Cellectis schedules business update for September 14
Biotechnology firm Cellectis will hold a conference call and webcast on September 14, 2026, to provide an update on its business operations.
Clinical-stage biotechnology company Cellectis has announced a scheduled business update to take place on Monday, September 14, 2026. The company will conduct the update through both a conference call and a live webcast.
The event is scheduled to accommodate different regions, with an English-language session at 8:00 a.m. ET (2:00 p.m. CET) followed by a French-language session at 9:00 a.m. ET (3:00 p.m. CET). Investors and interested parties can join via provided webcast links or through international dial-in numbers.
Cellectis, which specializes in gene editing and cell therapy, frequently uses these updates to communicate progress on its clinical pipeline. Such sessions are critical for stakeholders monitoring the company's research and development milestones.
A replay of the event will be accessible via the company's investor relations website following the conclusion of the broadcasts.